Huge demand for eye drug Vabysmo helped Roche avoid sales shrinkage in 2023, and its expected continued growth in 2024 will give the company breathing space to continue building its pipeline and streamlining its R&D organization.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?